-
Je něco špatně v tomto záznamu ?
Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry
G. Renda, L. Pecen, G. Patti, F. Ricci, D. Kotecha, JM. Siller-Matula, RB. Schnabel, R. Wachter, JM. Sellal, M. Rohla, M. Lucerna, K. Huber, FWA. Verheugt, JL. Zamorano, B. Brüggenjürgen, H. Darius, M. Duytschaever, JY. Le Heuzey, RJ. Schilling,...
Jazyk angličtina Země Itálie
Typ dokumentu časopisecké články, multicentrická studie, pozorovací studie
Grantová podpora
CDF-2015-08-074
Department of Health - United Kingdom
NLK
ProQuest Central
od 2006-04-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2006-01-01 do Před 1 rokem
Nursing & Allied Health Database (ProQuest)
od 2006-04-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 2006-04-01 do Před 1 rokem
- MeSH
- aplikace orální MeSH
- dabigatran aplikace a dávkování MeSH
- fibrilace síní farmakoterapie mortalita MeSH
- inhibitory faktoru Xa aplikace a dávkování MeSH
- lidé MeSH
- prospektivní studie MeSH
- pyrazoly aplikace a dávkování MeSH
- pyridony aplikace a dávkování MeSH
- registrace MeSH
- rivaroxaban aplikace a dávkování MeSH
- senioři MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- pozorovací studie MeSH
- Geografické názvy
- Evropa MeSH
The management of patients with atrial fibrillation (AF) has rapidly changed with increasing use of non-vitamin K antagonist oral anticoagulants (NOACs) and changes in the use of rhythm control therapy. The prevention of thromboembolic events European Registry in Atrial Fibrillation Prolongation Registry (PREFER Prolongation) enrolled consecutive patients with AF on NOACs between 2014 and 2016 in a multicentre, prospective, observational study with one-year follow-up, focusing on the time of introduction of NOACs. Overall, 3783 patients were enrolled, with follow-up information available in 3223 (85%). Mean age was 72.2 ± 9.4 years, 40% were women, mean CHA2DS2VASc score was 3.4 ± 1.6, and 2587 (88.6%) had a CHA2DS2VASc score ≥ 2. Rivaroxaban was used in half of patients, and dabigatran and apixaban were used in about a quarter of patients each; edoxaban was not available for use in Europe at the time. Major cardiovascular event rate was low: serious events occurred in 74 patients (84 events, 2%), including 24 strokes (1%), 62 major bleeds (2%), of which 30 were life-threatening (1%) and 3 intracranial (0.1%), and 28 acute coronary syndromes (1%). Mortality was 2%. Antiarrhythmic drugs were used in about 50% of patients, catheter ablation in 5%. Adverse events were low in this contemporary European cohort of unselected AF patients treated with NOACs already at the time of their first introduction, despite high thromboembolic risk.
1st Department of Cardiology Poznan University of Medical Sciences Poznan Poland
3rd Medical Department Cardiology and Intensive Care Medicine Wilhelminen Hospital Vienna Austria
Clinic and Policlinic for Cardiology University Hospital Leipzig Leipzig Germany
Daiichi Sankyo Europe Munich Germany
Department for General and Interventional Cardiology University Heart Center Hamburg Hamburg Germany
Department of Cardiology Medical University of Vienna Vienna Austria
Department of Cardiology Sint Jan Hospital Bruges Bruges Belgium
Department of Cardiology University Hospital of Nancy Nancy France
Department of Cardiology University Hospital Ramo´N Y Cajal Madrid Spain
DZHK Partner site Göttingen Germany
Emeritus Professor of Cardiology Amsterdam The Netherlands
Georges Pompidou Hospital René Descartes University Paris France
German Center for Cardiovascular Research Partner Site Hamburg Kiel Lübeck Hamburg Germany
Institute for Health Economics Steinbeis University Berlin Germany
Institute of Computer Science Academy of Sciences of the Czech Republic Prague Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21025903
- 003
- CZ-PrNML
- 005
- 20211026133406.0
- 007
- ta
- 008
- 211013s2021 it f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s11739-020-02442-9 $2 doi
- 035 __
- $a (PubMed)32955677
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a it
- 100 1_
- $a Renda, Giulia $u Department of Neuroscience, Imaging, and Clinical Science, G. D'Annunzio University of Chieti-Pescara, Chieti, Italy
- 245 10
- $a Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry / $c G. Renda, L. Pecen, G. Patti, F. Ricci, D. Kotecha, JM. Siller-Matula, RB. Schnabel, R. Wachter, JM. Sellal, M. Rohla, M. Lucerna, K. Huber, FWA. Verheugt, JL. Zamorano, B. Brüggenjürgen, H. Darius, M. Duytschaever, JY. Le Heuzey, RJ. Schilling, P. Kirchhof, R. De Caterina
- 520 9_
- $a The management of patients with atrial fibrillation (AF) has rapidly changed with increasing use of non-vitamin K antagonist oral anticoagulants (NOACs) and changes in the use of rhythm control therapy. The prevention of thromboembolic events European Registry in Atrial Fibrillation Prolongation Registry (PREFER Prolongation) enrolled consecutive patients with AF on NOACs between 2014 and 2016 in a multicentre, prospective, observational study with one-year follow-up, focusing on the time of introduction of NOACs. Overall, 3783 patients were enrolled, with follow-up information available in 3223 (85%). Mean age was 72.2 ± 9.4 years, 40% were women, mean CHA2DS2VASc score was 3.4 ± 1.6, and 2587 (88.6%) had a CHA2DS2VASc score ≥ 2. Rivaroxaban was used in half of patients, and dabigatran and apixaban were used in about a quarter of patients each; edoxaban was not available for use in Europe at the time. Major cardiovascular event rate was low: serious events occurred in 74 patients (84 events, 2%), including 24 strokes (1%), 62 major bleeds (2%), of which 30 were life-threatening (1%) and 3 intracranial (0.1%), and 28 acute coronary syndromes (1%). Mortality was 2%. Antiarrhythmic drugs were used in about 50% of patients, catheter ablation in 5%. Adverse events were low in this contemporary European cohort of unselected AF patients treated with NOACs already at the time of their first introduction, despite high thromboembolic risk.
- 650 _2
- $a aplikace orální $7 D000284
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a fibrilace síní $x farmakoterapie $x mortalita $7 D001281
- 650 _2
- $a dabigatran $x aplikace a dávkování $7 D000069604
- 650 _2
- $a inhibitory faktoru Xa $x aplikace a dávkování $7 D065427
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a pyrazoly $x aplikace a dávkování $7 D011720
- 650 _2
- $a pyridony $x aplikace a dávkování $7 D011728
- 650 _2
- $a registrace $7 D012042
- 650 _2
- $a rivaroxaban $x aplikace a dávkování $7 D000069552
- 651 _2
- $a Evropa $x epidemiologie $7 D005060
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a pozorovací studie $7 D064888
- 700 1_
- $a Pecen, Ladislav $u Institute of Computer Science, Academy of Sciences of the Czech Republic, Prague, Czech Republic
- 700 1_
- $a Patti, Giuseppe $u Department of Translational Medicine, University of Eastern Piedmont and Maggiore Della Carità Hospital, Novara, Italy
- 700 1_
- $a Ricci, Fabrizio $u Department of Neuroscience, Imaging, and Clinical Science, G. D'Annunzio University of Chieti-Pescara, Chieti, Italy
- 700 1_
- $a Kotecha, Dipak $u University of Birmingham Institute of Cardiovascular Sciences, and UHB and SWBH NHS Trusts, Birmingham, UK
- 700 1_
- $a Siller-Matula, Jolanta M $u Department of Cardiology, Medical University of Vienna, Vienna, Austria $u First Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland
- 700 1_
- $a Schnabel, Renate B $u Department for General and Interventional Cardiology, University Heart Center Hamburg, Hamburg, Germany $u German Center for Cardiovascular Research (DZHK) Partner Site Hamburg / Kiel/ Lübeck, Hamburg, Germany
- 700 1_
- $a Wachter, Rolf $u Clinic and Policlinic for Cardiology, University Hospital Leipzig, Leipzig, Germany $u DZHK (German Centre for Cardiovascular Research), Partner site, Göttingen, Germany
- 700 1_
- $a Sellal, Jean-Marc $u Department of Cardiology, University Hospital of Nancy, Nancy, France
- 700 1_
- $a Rohla, Miklos $u Third Medical Department, Cardiology and Intensive Care Medicine, Wilhelminen Hospital, Vienna, Austria
- 700 1_
- $a Lucerna, Markus $u Daiichi-Sankyo Europe, Munich, Germany
- 700 1_
- $a Huber, Kurt $u Third Medical Department, Cardiology and Intensive Care Medicine, Wilhelminen Hospital, and Sigmund Freud University, Medical School, Vienna, Austria
- 700 1_
- $a Verheugt, Freek W A $u Emeritus Professor of Cardiology, Amsterdam, The Netherlands
- 700 1_
- $a Zamorano, Jose Luis $u Department of Cardiology, University Hospital Ramo´N Y Cajal, Madrid, Spain
- 700 1_
- $a Brüggenjürgen, Bernd $u Institute for Health Economics, Steinbeis-University, Berlin, Germany
- 700 1_
- $a Darius, Harald $u Vivantes Hospital Neukölln, Berlin, Germany
- 700 1_
- $a Duytschaever, Mattias $u Department of Cardiology, Sint-Jan Hospital Bruges, Bruges, Belgium
- 700 1_
- $a Le Heuzey, Jean-Yves $u Georges Pompidou Hospital-René Descartes University, Paris, France
- 700 1_
- $a Schilling, Richard J $u London Bridge Hospital, London, UK
- 700 1_
- $a Kirchhof, Paulus $u University of Birmingham Institute of Cardiovascular Sciences, and UHB and SWBH NHS Trusts, Birmingham, UK
- 700 1_
- $a De Caterina, Raffaele $u Chair of Cardiology, University Cardiology Division, University of Pisa, Pisa University Hospital, Pisa, and Fondazione VillaSerena Per La Ricerca, Città Sant'Angelo, Pescara, Italy. raffaele.decaterina@unipi.it
- 773 0_
- $w MED00188089 $t Internal and emergency medicine $x 1970-9366 $g Roč. 16, č. 3 (2021), s. 591-599
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32955677 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20211013 $b ABA008
- 991 __
- $a 20211026133412 $b ABA008
- 999 __
- $a ok $b bmc $g 1714804 $s 1146410
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 16 $c 3 $d 591-599 $e 20200921 $i 1970-9366 $m Internal and emergency medicine $n Intern Emerg Med $x MED00188089
- GRA __
- $a CDF-2015-08-074 $p Department of Health $2 United Kingdom
- LZP __
- $a Pubmed-20211013
